newsfilter
← Latest News
PR Newswire·

TuHURA Biosciences Presents Data Demonstrating the Delta Opioid Receptor (DOR) as a New Target in Overcoming Acquired Resistance to Immune Checkpoint Inhibitors at the 57th ASH Annual Meeting and Exposition

TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel technologies to overcome resistance to cancer...